Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.

Abstract	Histone deacetylase inhibitors (HDACIs) represent a new class of targeted anti-cancer agents and different other diseases, like muscular disorders. A number of studies have shown that extracellular signal-activated kinases can target chromatin-modifying complexes directly and regulate their function. The molecular connection between the dystrophin-associated protein complex (DAPC) and chromatin has been described, by showing that NO signaling regulates histone deacetylase (HDAC) activity and influences gene expression in different cell types. In present study, we investigated HDACs changes in HeLa cells undergoing growth inhibition and apoptosis, caused by HDACI BML-210 and retinoic acid (ATRA). Cell cycle analysis indicated that HeLa cell treatment with 20 and 30 μM concentration of BML-210 increased the proportion of cells in G0/G1 phase, and caused accumulation in subG1, indicating that the cells are undergoing apoptosis. We determined down-regulation of HDAC 1-5 and 7 after treatment with BML-210. Also, we demonstrated expression of different isoforms of alpha-dystrobrevin (α-DB) and other components of DAPC such as syntrophin, dystrophin, beta-dystrobrevin (β-DB) and NOS in HeLa cells after treatments. We determined changes in protein expression level of dystrophin, NOS1, α- and β-DB and in subcellular localization of α-DB after treatments with BML-210 and ATRA. In conclusion, these results suggest that HDACI BML-210 can inhibit cell growth and induce apoptosis in cervical cancer cells, what correlates with down-regulation of HDAC class I and II and changes in the DAPC expression levels. This can be important for identifying target proteins in DAPC signaling to HDACs, as a target of pharmacological intervention for treatment of muscular dystrophies and other diseases.
Authors	Veronika V Borutinskaite, Karl-Eric Magnusson, Ruta Navakauskiene
Journal	Molecular biology reports (Mol Biol Rep) Vol. 39 Issue 12 Pg. 10179-86 (Dec 2012) ISSN: 1573-4978 [Electronic] Netherlands
PMID	23007576 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Anilides Antineoplastic Agents Calcium-Binding Proteins Dystrophin Dystrophin-Associated Protein Complex Dystrophin-Associated Proteins Histone Deacetylase Inhibitors Membrane Proteins Muscle Proteins N1-(2-aminophenyl)-N8-phenyloctanediamide dystrobrevin syntrophin alpha1 Tretinoin Nitric Oxide Synthase Histone Deacetylases
Topics	Anilides (pharmacology) Antineoplastic Agents (pharmacology) Apoptosis (drug effects) Calcium-Binding Proteins (metabolism) Cell Cycle (drug effects) Cell Proliferation (drug effects) Cell Survival (drug effects) Down-Regulation Drug Synergism Dystrophin (metabolism) Dystrophin-Associated Protein Complex (genetics, metabolism) Dystrophin-Associated Proteins (metabolism) Female Gene Expression (drug effects) Gene Expression Regulation, Neoplastic (drug effects) HeLa Cells Histone Deacetylase Inhibitors (pharmacology) Histone Deacetylases (genetics, metabolism) Humans Membrane Proteins (metabolism) Muscle Proteins (metabolism) Muscular Dystrophies (drug therapy) Nitric Oxide Synthase (metabolism) Protein Transport Tretinoin (pharmacology) Uterine Cervical Neoplasms

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!